Caliper Life Sciences, Inc. (NASDAQ: CALP) this week introduced its latest video-imaging system. The IVIS Kinetic system is designed to see activity at the molecular level through non-invasive means. It’s the latest in a long line of preclinical imaging systems, including high-sensitivity bioluminescence and fluorescence molecular. The main difference is the video capability. This additional capability, the company states in a news release, “will further advance cardiovascular, neurology, immunology and oncology distribution studies conducted.”

The IVIS system enhances analysis of gene expression, cellular pathways and the body’s response to drugs. The current and intended application of the imaging is to track speed of reaction with drug use in lab animals and any different behaviors in lab animals.

“The IVIS Kinetic imaging system provides a window for scientists to view biological events as they happen,” said Kevin Hrusovsky, Caliper Life Sciences president and CEO. “This system is another great example of how Caliper Life Sciences is helping pharma and biotech companies understand complex biological processes to accelerate the discovery of successful drug candidates.”

Caliper’s IVIS imaging systems have played a significant role in demonstrating the usefulness of various drugs, including Sutent (Pfizer), Sprycel (Bristol-Myers Squibb), Tasigna ((Novartis), and Cubicin (Cubist Pharmaceuticals).

Let us hear your thoughts below: